



1625  
Ifu

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): CHENG et al.  
SERIAL NO.: 10/586,822  
FILED: 07/19/2006  
FOR: COMPOUNDS AND METHODS TO INCREASE ANTI-P-  
GLYCOPROTEIN ACTIVITY OF BAICALEIN BY  
ALKYLATION ON THE A RING  
INT'L. APPLN. NO.: PCT/US2005/002910  
INT'L. FILING DATE: 31 January 2005  
GROUP ART UNIT: Not yet available  
EXAMINER: Not yet available

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 223313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56(a), applicant encloses herewith a copy of Form PTO-1449 listing documents relevant to the background of the invention described and claimed in the above-identified application. Inclusion of a reference on this list does not necessarily imply that that reference is prior art. For the convenience of the Examiner, copies of the listed non-U.S. patent documents are enclosed.

Applicant respectfully requests that the Examiner consider the enclosed references in determining the patentability of the claimed invention. Applicant also requests that the Examiner return a copy of enclosed Form PTO-1449 with initials or other marks indicating that the references have been so considered. If any fee is due, please charge/credit deposit account no. 04-0838.

Respectfully submitted,

Coleman Sudol Sapone, P.C.

By: 

Henry D. Coleman


Reg. No. 32,559

714 Colorado Avenue

Bridgeport, Connecticut 06605-1601

(203)366-3560

Dated: October 12, 2006



### **CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to: "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" on October 12, 2006.

*Harold Hull*

\_\_\_\_\_  
Harold Hull

**INFORMATION DISCLOSURE  
CITATION IN AN APPLICATION**Att'y Ref:  
Y03-097US Nat

Serial No: 10/586,822

Applicant: CHENG, Yung-chi et al.

Filing Date: 07/19/2006

Art Unit:

**United States Patent Documents**

| Examiner<br>Initial | Document<br>Number | Date | Name | Class | Subclass | Filing Date |
|---------------------|--------------------|------|------|-------|----------|-------------|
|                     |                    |      |      |       |          |             |

**Foreign Patent Documents**

| Examiner<br>Initial | Publication<br>Number | Publication<br>Date | Country | Class | Subclass | Translation |    |
|---------------------|-----------------------|---------------------|---------|-------|----------|-------------|----|
|                     |                       |                     |         |       |          | Yes         | No |
|                     |                       |                     |         |       |          |             |    |
|                     |                       |                     |         |       |          |             |    |

| Examiner<br>Initial | Other Documents (by Title, Author Date, Pertinent Pages, Etc.)   |
|---------------------|--|
|                     | German, U. A. P-glycoprotein--a mediator of multidrug resistance in tumour cells. <i>Eur J Cancer</i> <b>1996</b> , 32A, 927-944                           |
|                     | Gottesman, M. M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. <i>Annu Rev Biochem</i> <b>1993</b> , 62, 385-427 |

Examiner:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered; Include a copy of this form with next communication to the applicant.

|  |   |
|--|---|
|  | Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M. M.; Pastan, I. et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. <i>Proc Natl Acad Sci USA</i> <b>1987</b> , <i>84</i> , 7735-7738  |
|  | Borst, P.; Schinkel, A. H. What have we learnt thus far from mice with disrupted P-glycoprotein genes? <i>Eur J Cancer</i> <b>1996</b> , <i>32A</i> , 985-990   |
|  | Luker, G. D.; Nilsson, K. R.; Covey, D. F.; Piwmica-Worms, D. Multidrug resistance (MDRI) P-glycoprotein enhances esterification of plasma membrane cholesterol. <i>J Biol Chem</i> <b>1999</b> , <i>274</i> , 6979-6991  |
|  | Dalton, W. S.; Grogan, T. M.; Meltzer, P. S.; Scheper, R. J.; Dude, B. G. et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. <i>J Clin Oncol</i> <b>1989</b> , <i>7</i> , 415-424 |
|  | Miller, T. P.; Grogan, T. M.; Dalton, W. S.; Spier, C. M.; Scheper, R. J. et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. <i>J Clin Oncol</i> <b>1991</b> , <i>9</i> , 17-24                                |
|  | Nuessler, V.; Scheulen, M. E.; Oberneder, R.; Kriegmair, M.; Goebel, K. J. et al. Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL. <i>Eur J Med Res</i> <b>1997</b> , <i>2</i> , 55-61   |
|  | Wilson, W. H.; Jamis-Dow, C.; Bryant, G.; Balis, F. M.; Klecker, R. W. et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexveraparnil with EPOCH chemotherapy. <i>J Clin Oncol</i> <b>1995</b> , <i>13</i> , 1985-1994  |
|  | Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. <i>Cancer Res</i> <b>1993</b> , <i>53</i> , 4595-4602   |
|  | Boesch, D.; Gaveriaux, C.; Jachez, B.; Pourtier-Manzanedo, A.; Bollinger, P. et al. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. <i>Cancer Res</i> <b>1991</b> , <i>51</i> , 4226-4233  |
|  | Ramu, A.; Spanier, R.; Rahamimoff, H.; Fuks, Z. Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells. <i>Br J Cancer</i> <b>1984</b> , <i>50</i> , 501-507  |
|  | Middleton, E., Jr.; Kandaswami, C.; Theoharides, T. C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. <i>Pharmacol Rev</i> <b>2000</b> , <i>52</i> , 673-751   |
|  | Bailey, D. G.; Malcolm, J.; Arnold, O.; Spence, J. D. Grapefruit juice-drug interactions. <i>Br J Clin Pharmacol</i> <b>1998</b> , <i>46</i> , 101-110  |
|  | Ducharme, M. P.; Warbasse, L. H.; Edwards, D. J. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. <i>Clin Pharmacol Ther</i> <b>1995</b> , <i>57</i> , 485-491  |
|  | De Vincenzo, R.; Scambia, G.; Benedetti Panici, P.; Ranelletti, F. O.; Bonanno, G. et al. Effect of synthetic and naturally occurring chalcones on ovarian cancer cell growth: structure-activity   |

|   |                  |
|---|------------------|
| Examiner:   | Date Considered: |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered; Include a copy of this form with next communication to the applicant. |                  |

|  |  |
|--|--|
|  | relationships. <i>Anticancer Drug Des</i> 1995, 10, 481-490  |
|  | Murakami, S.; Muramatsu, M.; Tomisawa, K. Inhibition of gastric H <sup>+</sup> , K <sup>(+)</sup> -ATPase by flavonoids: a structure-activity study. <i>J Enzyme brhib</i> 1999, 14, 151-166   |
|  | Akiyama, T.; Ishida, J.; Nakagawa, S.; Ogawara, H.; Watanabe, S. et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. <i>J Biol Chem</i> 1987, 262, 5592-5595  |
|  | De Azevedo, W. F., Jr.; Mueller-Dieckmann, H. J.; Schulze-Gahmen, U.; Worland, P. J.; Sausville, E. et al. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. <i>Proc Natl Acad Sci USA</i> 1996, 93, 2735-2740   |
|  | Boumendjel, A.; Di Pietro, A.; Dumontet, C.; Barron, D. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. <i>Med Res Rev</i> 2002, 22, 512-529   |
|  | Conseil, G.; Baubichon-Cortay, H.; Dayan, G.; Jault, J. M.; Barron, D. et al. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. <i>Proc Natl Acad Sci USA</i> 1998, 95, 9831-9836  |
|  | Perez-Victoria, J. M.; Perez-Victoria, F. J.; Conseil, G.; Maitrejean, M.; Comte, G. et al. High-affinity binding of silybin derivatives to the nucleotide-binding domain of a <i>Leishmania tropica</i> P-glycoprotein-like transporter and chemosensitization of a multidrugresistant parasite to daunomycin. <i>Antimicrob Agents Chemother</i> 2001, 45, 439-446 |
|  | Thiyagarajah, P.; Kuttan, S. C.; Lim, S. C.; Teo, T. S.; Das, N. P. Effect of myricetin and other flavonoids on the liver plasma membrane Cat <sup>+</sup> pump. Kinetics and structure-function relationships. <i>Biochem Pharmacol</i> 1991, 41, 669-675   |
|  | Hirano, T.; Oka, K.; Akiba, M. Effects of synthetic and naturally occurring flavonoids on Na <sup>+</sup> ,K <sup>+</sup> -ATPase: aspects of the structure-activity relationship and action mechanism. <i>Life Sci</i> 1989, 45, 1111-1117  |
|  | Jinsart, W.; Ternai, B.; Polya, G. M. Inhibition of rat liver cyclic AMP-dependent protein kinase by flavonoids. <i>Biol Chem Hoppe Seyler</i> 1992, 373, 205-211  |
|  | Ferriola, P. C.; Cody, V.; Middleton, E., Jr. Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. <i>Biochein Pharmacol</i> 1989, 38, 1617-1624  |
|  | Hagiwara, M.; Inoue, S.; Tanaka, T.; Nunoki, K.; Ito, M. et al. Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases. <i>Biochem Pharmacol</i> 1988, 37, 2987-2992  |
|  | Perez-Victoria, J. M.; Chiquero, M. J.; Conseil, G.; Dayan, G.; Di Pietro, A. et al. Correlation between the affinity of flavonoids binding to the cytosolic site of <i>Leishmania tropica</i> multidrug transporter and their efficiency to revert parasite resistance to daunomycin. <i>Biochemistry</i> 1999, 38, 1736-1743                                       |
|  | Lo, A.; Burckart, G. J. P-glycoprotein and drug therapy in organ transplantation. <i>J Clin Pharniacol</i> 1999, 39, 995-1005  |

|   |                  |
|---|------------------|
| Examiner:   | Date Considered: |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered; Include a copy of this form with next communication to the applicant. |                  |

|  |  |
|--|--|
|  | Wang, R. B.; Kuo, C. L.; Lien, L. L.; Lien, E. J. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. <i>J Clin Pharm Ther</i> 2003, 28, 203-228  |
|  | Di Pietro, A.; Conseil, G.; Perez-Victoria, J. M.; Dayan, G.; Baubichon-Cortay, H. et al. Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. <i>Cell Mol Life Sci</i> 2002, 59, 307-322        |
|  | Chambers, T. C.; Pohl, J.; Raynor, R. L.; Kuo, J. F. Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. <i>J Biol Chem</i> 1993, 268, 4592-4595  |
|  | Callaghan, R.; Higgins, C. F. Interaction of tamoxifen with the multidrug resistance P-glycoprotein. <i>Br J Cancer</i> 1995, 71, 294-299  |
|  | Smith, C. D.; Zilfou, J. T. Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. <i>JBiol Chem</i> 1995, 270, 28145-28152  |
|  | Conseil, G.; Perez-Victoria, J. M.; Jault, J. M.; Gamarro, E.; Goffeau, A. et al. Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity. <i>Biochemistry</i> 2001, 40, 2564-2571  |
|  | Dayan, G.; Jault, J. M.; Baubichon-Cortay, H.; Baggetto, L. G.; Renoir, J. M. et al. Binding of steroid modulators to recombinant cytosolic domain from mouse P-glycoprotein in close proximity to the ATP site. <i>Biochemistry</i> 1997, 36, 15208-15215 |
|  | Chen, H. X.; Bamberger, U.; Heckel, A.; Guo, X.; Cheng, Y. C. BIBW 22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport. <i>Cancer Res</i> 1993, 53, 1974-1977         |
|  | Park, S. Y.; Lam, W.; Cheng, Y. C. X-ray repair cross-complementing gene 1 protein plays an important role in camptothecin resistance. <i>Cancer Res</i> 2002, 62, 459-465   |
|  |  |
|  |  |
|  |  |
|  |  |

|   |                  |
|---|------------------|
| Examiner:   | Date Considered: |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered; Include a copy of this form with next communication to the applicant. |                  |